The primary objective of this study is to assess the absolute bioavailability and to evaluate pharmacokinetic parameters of a single oral dose and a radiolabelled intravenous microdose of \[14C\]AZD9668 in healthy male subjects.
This is an exploratory study to assess the absolute bioavailability of a single oral dose of AZD9668 with respect to an intra-venous microdose of \[14C\]AZD9668 in healthy male subjects.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
6
Tablets of AZD9668 and IV dose of \[C14\]AZD9668
Research Site
Ruddington, Nottingham, United Kingdom
Research Site
London, United Kingdom
The absolute bioavailability and evaluation of pharmacokinetic parameters (AUC, AUC (0-t), Cmax, t½, tmax, and MRT of of a single oral dose and a radiolabelled intravenous microdose of [14C]AZD9668
Time frame: Multiple Pharmacokinetic blood samples for up to 96 hours following drug administration
Safety and tolerability of AZD9668: Adverse events, clinical chemistry, haematology, urinalysis, vital signs, electrocardiogram, physical examination
Time frame: measured within 21 days of drug administration and up to 7 days following drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.